The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index; 4 of the 10 sources its claims cite were checked for support.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Open accessAbstract
BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma. METHODS: CAR-positive (CAR+) T cells. The primary end point was an overall response (partial response or better); a key secondary end point was a complete response or better (comprising complete and stringent complete responses). RESULTS: nucleated cells) was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better. The median progression-free survival was 8.8 months (95% confidence interval, 5.6 to 11.6). Common toxic effects among the 128 treated patients included neutropenia in 117 patients (91%), anemia in 89 (70%), and thrombocytopenia in 81 (63%). Cytokine release syndrome was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher. Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%); no neurotoxic effects higher than grade 3 occurred. Cellular kinetic analysis confirmed CAR+ T cells in 29 of 49 patients (59%) at 6 months and 4 of 11 patients (36%) at 12 months after infusion. CONCLUSIONS: Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost all patients had grade 3 or 4 toxic effects, most commonly hematologic toxic effects and cytokine release syndrome. (Funded by bluebird bio and Celgene, a Bristol-Myers Squibb company; KarMMa ClinicalTrials.gov number, NCT03361748.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 of 10 cited sources checked · 2 supported · 0 flagged · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“The B-cell maturation antigen (BCMA)-directed CAR T cell idecabtagene vicleucel (ide-cel, also called bb2121) showed promising efficacy in a phase 1 study involving patients with relapsed or refractory myeloma.11”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > D
What the sources say
- Supportedcites [11] 11. Raje N, Berdeja J, Lin Y, et al. Anti- BCMA CAR T-cell therapy bb2121 in re- lapsed or refractory multiple myeloma. N Engl J Med 2019; 380: 1726-37. source
The Methods identify bb2121 as an anti-BCMA CAR T-cell therapy studied in a phase 1 trial involving patients with relapsed or refractory multiple myeloma. The Discussion reports an 85% clinical response rate, supporting the characterization of its efficacy as promising. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These efficacy results compare favorably with results in similarly heavily pretreated patients with relapsed or refractory myeloma treated with two recently approved regimens, selinexor plus dexamethasone and belantamab mafodotin (median progression-free survival, 3.7 months and 2.9 months, respectively).5,17”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Supportedcites [5] 5. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019; 381: 727-38. source
The Methods and Discussion describe patients with triple-class refractory myeloma who were heavily pretreated, with a median of seven previous regimens. The Efficacy section reports median progression-free survival of 3.7 months with selinexor plus dexamethasone. This citation supports the selinexor result; the separate belantamab result is not attributed to this paper. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [17] 17. Lonial S, Lee HC, Badros A, et al. Belan- tamab mafodotin for relapsed or refracto- ry multiple myeloma (DREAMM-2): a two- arm, randomised, open-label, phase 2 study. Lancet Oncol 2020; 21: 207-21. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: Cross-trial comparisons of progression-free survival between the KarMMa study and trials of selinexor plus dexamethasone or belantamab mafodotin are valid.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Observed toxic effects were consistent with those in previous reports.11”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Partly supportedcites [11] 11. Raje N, Berdeja J, Lin Y, et al. Anti- BCMA CAR T-cell therapy bb2121 in re- lapsed or refractory multiple myeloma. N Engl J Med 2019; 380: 1726-37. sourceExperimental — accuracy not yet measured
The Results (Safety; page unavailable) document the observed toxic effects. The Discussion compares them with previous studies, but reports a lower incidence of severe cytokine release syndrome with bb2121 and cautions that cross-study comparisons are complicated. It does not establish that the toxic effects were generally consistent with previous reports. (LLM, conf=0.82)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Duration of undetectable sBCMA correlated with response duration, and clearance of sBCMA at month 2 was associated with longer progression-free survival (Fig. S5E and S5F).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Figure 2 (facing page). Progression-free Survival, Duration of Response, and Overall Survival.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with peak levels higher in patients having cytokine release syndrome of grade 3 or higher (Fig. S6).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a somewhat higher frequency and somewhat greater depth of response were observed at the 450 × 10 6 dose (response in 81% of the pa-tients and complete response or better in 39%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At baseline, 110 of 112 tumor samples (98%) expressed BCMA, with 109 having at least 50% BCMA-positive plasma cells, and all the patients had detectable levels of sBCMA.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Figure 2 (facing page). Progression-free Survival, Duration of Response, and Overall Survival.
Strength:plain· not yet calibratedn = 112Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A response was observed in 73% of the treated patients, and a complete response or better was observed in 33%;”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline cytokine levels were not associated with higher-grade cytokine release syndrome or neurotoxic effects.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with an incidence of response to bridging therapy of 4%”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 12
- It may state two separate claims as one. 32
- The quote only partly states this claim. 1
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In contrast, CD19 epitope loss is reported to be a relatively common escape mechanism after treatment with CD19-directed CAR T-cell therapy, especially in patients with acute leukemia.18,19”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Partly supportedcites [18] 18. Cheng J, Zhao L, Zhang Y, et al. Un- derstanding the mechanisms of resis- tance to CAR T-cell therapy in malignan- cies. Front Oncol 2019; 9: 1237. sourceExperimental — accuracy not yet measured
The Tumor Factors section reports that loss of the targeted CD19 epitope enabled escape after anti-CD19 CAR T-cell therapy in relapsed B-ALL. It also reports that target-antigen-negative relapse accounts for approximately 9–25% of B-ALL relapses, but does not establish that epitope loss specifically is relatively common or more common in acute leukemia than in other malignancies. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [19] 19. Badar T, Shah NN. Chimeric antigen receptor T cell therapy for acute lympho- blastic leukemia. Curr Treat Options On- col 2020; 21: 16. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with persistent grade 3 or 4 neutropenia (52 patients) or thrombocytopenia (62 patients) 1 month after infusion, the median time to recovery to grade 2 or lower was 1.9 months (range, 1.2 to 5.6) and 2.1 months (range, 1.2 to 13.8), respectively”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 52Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimated median progression-free survival was 8.8 months overall (95% CI, 5.6 to 11.6), 12.1 months (95% CI, 8.8 to 12.3) at the 450 × 10 6 dose, and 20.2 months (95% CI, 12.3 to could not be estimated) in patients having a complete or stringent complete response”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 128 treated patients had received a median of 6 previous antimyeloma regimens (range, 3 to 16), and 120 (94%) had received previous autologous hematopoietic stem-cell transplants (Table 1).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Patients
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although high interpatient variability was observed at all doses, upper quartiles of exposure (area under the curve of the transgene level from time of dose to 28 days [AUC 0-28 days ]) were observed more frequently at the 450 × 10 6 dose (Fig. 3B).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among treated patients, 5 were positive for antidrug antibodies before infusion.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline sBCMA levels were elevated in treated patients and de-creased rapidly after infusion in patients who had a response, with nadir values achieved within 3 months (Fig. 3A and Fig. S5B and S5C).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%); no neurotoxic effects higher than grade 3 occurred.”
- Also stated in: § Table 1. (Continued.) · plain
“Investigator-identified neurotoxic effects were reported in 23 patients (18%), of whom 4 (3%) had grade 3 events; no grade 4 or 5 neu-rotoxic effects were observed”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Table 1. (Continued.) · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time to first response was 1.0 month (range, 0.5 to 8.8); the median time to a complete response or better was 2.8 months (range, 1.0 to 11.8).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, neurotoxic effects of any grade were reported in 0 of 4 patients, 12 of 70 patients (17%), and 11 of 54 patients (20%), respectively, with grade 3 events in 0 patients, 1 patient (1%), and 3 patients (6%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 54Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Antidrug antibodies had no effect on the incidence of response or of complete response or better and had no noticeable effect on progression-free survival.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The absence of a detectable effect of antidrug antibodies on efficacy is not due to insufficient statistical power.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimated median overall survival was 19.4 months (95% CI, 18.2 to could not be estimated), with an overall survival of 78% at 12 months (Fig. 2D).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Exposures were higher in patients who had a response than in those who did not (Fig. S5A), and higher exposure was associated with deeper response and longer progression-free survival (Fig. 3C and 3D).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Achievement of undetectable sBCMA levels increased with depth of response (17 of 27 pa-”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe quote only partly states this claim.
- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, cytokine release syndrome of any grade was observed in 2 of 4 patients (50%), 53 of 70 patients (76%), and 52 of 54 patients (96%), respectively, with cytokine release syndrome of grade 3 or higher observed in 0 patients, 4 patients (6%), and 3 patients (6%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimate for median duration of response was 10.7 months (95% CI, 9.0 to 11.3) overall and 11.3 months (95% CI, 10.3 to 11.4) at the 450 × 10 6 dose”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher.”
- Also stated in: § Table 1. (Continued.) · plain
“Cytokine release syndrome occurred in 107 patients (84%) and was mostly of grade 1 or 2 (Table 2 and Table S10).Five patients (4%) had grade 3 cytokine release syndrome, 1 (<1%) had grade 4, and 1 (<1%) had grade 5 (300 × 10 6 dose level).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Table 1. (Continued.) · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 88 patients (69%) and were of grade 3 or 4 in 28 (22%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 88Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“including many with a high tumor burden, high-risk cytogenetic abnormalities, and extramedullary disease.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Common toxic effects among the 128 treated patients included neutropenia in 117 patients (91%), anemia in 89 (70%), and thrombocytopenia in 81 (63%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After disease progression, 28 patients were retreated with ide-cel (Table S4).Six patients (21%) had a second response, with durations of response ranging from 1.9 to 6.8 months; all the patients who had a response were retreated at a dose higher than their initial dose.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most grade 3 or 4 events were hematologic toxic effects, including neutropenia in 114 patients (89%), anemia in 77 (60%), and thrombocytopenia in 67 (52%), and were at least partially related to the lymphodepleting chemotherapy administered before ide-cel infusion.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 114Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 44 treated patients (34%) died during the study, with most deaths (27) attributed by the investigator to complications of myeloma progression (Table S12).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 44Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Levels of proinflammatory markers, including cytokines, ferritin, and C-reactive protein, increased early after ide-cel infusion and decreased by month 1”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The response duration increased with the depth of response; the median response duration was 4.5 months (95% CI, 2.9 to 6.7), 10.4 months (95% CI, 5.1 to 11.3), and 19.0 months (95% CI, 11.3 to could not be estimated) in patients having a best response of partial response (27 patients), very good partial response (25 patients), and complete or stringent complete response (42 patients),”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the target doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, a response was observed in 2 of 4 patients (50%), in 48 of 70 patients (69%), and in 44 of 54 patients (81%), respectively, and a complete response or better was observed in 1 of 4 patients (25%), in 20 of 70 patients (29%), and in 21 of 54 patients (39%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients (4%) died after 6 months from unrelated adverse events, and an additional 8 patients (6%) died after disease progression.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 5Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Minimal residual disease (MRD)-negative status (<10 -5 nucleated cells) was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better.”
- Also stated in: § Efficacy · plain
“Of the 42 patients with a complete or stringent complete response, 33 (79%) also had MRDnegative status at a sensitivity level of 10 -5 , corresponding to 26% (95% CI, 19 to 34) of the treated population; the remaining 9 patients (21%) could not be evaluated for MRD”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 33Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Efficacy · plain
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“High-grade hematologic toxic effects were common but transient.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The fact that MRDnegative responses occurred in approximately a quarter of the patients highlights the depth of response induced by ide-cel.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: MRD negativity at a sensitivity of 10^-5 is a valid measure of depth of response and clinical benefit.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol was approved by local or independent institutional review boards or ethics committees at participating sites.All the patients provided written informed consent.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nearly all tumors expressed BCMA, a finding that supports the use of ide-cel in relapsed and refractory myeloma without restriction based on tumor BCMA expression.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: BCMA expression is required for ide-cel efficacy, so lack of tumor BCMA expression would limit its use.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary efficacy analysis was performed in the population of patients treated with ide-cel (128 patients).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Between December 13, 2017, and November 13, 2018, a total of 140 patients were enrolled and underwent leukapheresis, of whom 128 received ide-cel infusions.Twelve patients discontinued the study before ide-cel infusion (including 1 patient who discontinued after unsuccessful manufacture of the CAR T-cell product)”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Patients
Strength:plain· not yet calibratedn = 140Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was designed by the authors in conjunction with the sponsors and conducted in accordance with the International Council for Harmonisation guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sample size for the primary end point (overall response) was based on a onesample binomial test with normal approximation, under the assumption of 15% dropout between the time of enrollment and ide-cel treatment.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Statistical tests were not performed on subgroup analyses.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary end point was an overall response (partial response or better), defined according to IMWG Uniform Response Criteria for Multiple Myeloma 12 as assessed by an independent review committee.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“MRD negativity was evaluated in bone marrow aspirates by next-generation sequencing (clonoSEQ, Adaptive Biotechnologies) with a minimum cutoff of 10 -5 nucleated cells.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The actual doses delivered were within 20% of the target doses.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Design and Patients
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.Cytokine release syndrome was graded according to published criteria (Table S2).14”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Soluble BCMA is a serum-based universal marker of myeloma burden.
“Soluble BCMA was assessed as a serum-based universal marker of myeloma burden.”
The paper relies on this without support.
Cross-trial comparisons of progression-free survival between the KarMMa study and trials of selinexor plus dexamethasone or belantamab mafodotin are valid.
“These efficacy results compare favorably with results in similarly heavily pretreated patients with relapsed or refractory myeloma treated with two recently approved regimens, selinexor plus dexamethasone and belantamab mafodotin (median progression-free survival, 3.7 months and 2.9 months, respectively).5,17”
The paper relies on this without support.
MRD negativity at a sensitivity of 10^-5 is a valid measure of depth of response and clinical benefit.
“The fact that MRDnegative responses occurred in approximately a quarter of the patients highlights the depth of response induced by ide-cel.”
The paper relies on this without support.
BCMA expression is required for ide-cel efficacy, so lack of tumor BCMA expression would limit its use.
“Nearly all tumors expressed BCMA, a finding that supports the use of ide-cel in relapsed and refractory myeloma without restriction based on tumor BCMA expression.”
The paper relies on this without support.
The absence of a detectable effect of antidrug antibodies on efficacy is not due to insufficient statistical power.
“Antidrug antibodies had no effect on the incidence of response or of complete response or better and had no noticeable effect on progression-free survival.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are newly approved CAR-T products targeting BCMA that are active in relapsed refractory myeloma.89,90”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Safety of ide-cel remained consistent with the IA, with no parkinsonism, Guillain-Barré syndrome, or SPMs of T-cell origin reported. 13”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Common side effects such as CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were mostly low grade, indicating manageable toxicity.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The median duration of response (mDOR) was 11 months in patients achieving CR and 19 months in those achieving stringent complete response (sCR).”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Median DOR and PFS were 10.7 months and 8.8 months, respectively, for ide-cel, and were both not reached for cilta-cel5,6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although follow-up is still ongoing, among patients with ≥CR, DOR and PFS at 15 months with elranatamab were comparable to those observed with other BCMA-targeted T-cell-redirecting therapies, suggesting similar outcomes once a deep response is achieved5,24,25.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High response rates have been reported with the BCMA chimeric antigen receptor (CAR) T-cell therapies, ide-cel and cilta-cel, with responses reported in 73% and 97% of treated patients, respectively.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among 128 patients with relapsed refractory myeloma treated on a phase II trial, ide-cel was associated with a response rate of 73%.89 Thirty three percent of patients had a complete response or better. The median PFS was 8.8 months.”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome was seen in 84%, and 5% were grade 3 or higher. Neurotoxicity was seen in 18%, and was grade 3 in 3%.”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Chimeric antigen receptor (CAR) T-cell therapy has shown promising ef fi cacy in patients with TCE R/RMM. 13-21”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“In the KarMMa study involving 128 patients with RRMM, the overall response rate (ORR) to a single infusion of Abecma was 73%, with a complete response (CR) rate of 33%.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
The cited source says what the claim attributes to it.
In the citing paper
“Abecma has demonstrated the ability to induce rapid, deep, and long-lasting remissions with just one infusion, providing a new and effective personalized therapy option for MM patients [227, 243, 258, 259].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Recently approved therapies such as selinexor, 9 belantamab mafodotin, 10 idecabtagene vicleucel, 11 and ciltacabtagene autoleucel 12 have had clinical benefit in patients with relapsed or refractory multiple myeloma.”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [11]
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationOral selinexor-dexamethasone for triple-class refractory multiple myeloma.
Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903455 · Cited by 666
Self-citationOutcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Friedman, K. M., Garrett, T. E., Evans, J. W., Horton, H. M., Latimer, H. J., Seidel, S. L., Horvath, C. J., & Morgan, R. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.001 · Cited by 205
Treatment of relapsed and refractory multiple myeloma
Sonneveld, P., & Broijl, A. (2016) · Haematologica · doi:10.3324/haematol.2015.129189 · Cited by 181
CAR T-cell therapy in hematologic malignancies: a voyage in progress.
Holstein, S. A., & Lunning, M. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1674 · Cited by 172
Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., & Zhou, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01237 · Cited by 153
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 2,535
Mukhopadhyay, P., Abdullah, H. A., Opalinska, J., Paka, P., Richards, E., Weisel, K. C., Trudel, S., Mateos, M., Dimopoulos, M. A., & Lonial, S. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01212-0 · Cited by 21
Self-citationNew targets for CAR T therapy in hematologic malignancies
Savani, M., Oluwole, O. O., & Dholaria, B. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101277 · Cited by 17
Real-World Experience and Optimization of Outpatient Chimeric Antigen Receptor T Cell Therapy
McGann, M., Davis, J. A., Gaffney, K. J., Smith, D., Edwards, K. H., Hess, B. T., & Hashmi, H. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.06.021 · Cited by 17
Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon
Martino, M., Naso, V., Loteta, B., Canale, F. A., Pugliese, M., Alati, C., Musuraca, G., Nappi, D., Gaimari, A., Nicolini, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113332 · Cited by 17
“8 months, more significant than expected from other available therapies in heavily pretreated R/R MM [21].”
BackgroundShy, B. R., Vykunta, V. S., Ha, A. S., Roth, T. L., Talbot, A., Nguyen, D. N., Chen, Y. Y., Blaeschke, F., Vedova, S., Mamedov, M. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.02.458799 · Cited by 18
Marar, R. I., Abbasi, M. A., Prathivadhi-Bhayankaram, S. V., Daryanani, A. E., Villarraga, H. R., Anavekar, N. S., Bhatt, V. R., & Paludo, J. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00713 · Cited by 19
Iida, S., Ito, S., Yokoyama, H., Ishida, T., Nagai, Y., Handa, H., Ito, S., Kamei, Y., Nakamura, M., & Suzuki, K. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae068 · Cited by 16
“…were comparable to the 56.3% (with no grade ≥ 3 events) reported for the overall trial population and consistent with previous reports showing a trend for reduced CRS incidence and severity for bispecific antibodies compared with chimeric antigen receptor T-cell therapies for RRMM (16,31–33).”
BackgroundResultInfluentialAn, J., Zhao, J., Zou, P., Zhang, Y., Wei, J., Tian, W., & Wei, J. (2024) · Cancer Medicine · doi:10.1002/cam4.7372 · Cited by 16
“…), e (Logue et al. 32 ), f (Raje et al. 28 ), g (Josyula et al. 35 ), h (Zhou et al. 34 ), i (Hansen et al. 33 ), j (Cornell et al. 31 ), k (Kambhampat et al. 25 ), l (Berdeja et al. 29 ), m (Munshi et al. 48 ), n (Mailankody et al. 37 ), o (Wang et al. 26 ), p (Xu et al. 27 ), q (Mi et al. 36 ).”
Acute kidney injury following CAR-T cell therapy: a nephrologist’s perspective
Kanbay, M., Mizrak, B., Alper, E. N., et al. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae359 · Cited by 16
“…and the European Medicines Agency approved several CAR-T cell therapies such as tisagen-lecleucel and axicabtagene ciloleucel for relapsed or refractory large B cell lymphoma [5 , 6 ] and idecabtagene vicleucel and ciltacabtagene autoleucel for relapsed or refractory multiple myeloma [7 , 8 ].”
Kim, S. J., Mugundu, G. M., & Singh, A. P. (2024) · Clinical and Translational Science · doi:10.1111/cts.70101 · Cited by 18
Richardson, T., Schütte, D., Kobbe, G., Baermann, B.-N., Holderried, T., Schmitz, F., Crysandt, M., Hallek, M., Scheid, C., Holtick, U., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015008 · Cited by 16
Alfar, H. R., Chen, C., Lachacz, E. J., Tang, W., & Zhang, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1512494 · Cited by 15
“Therefore, the presence of ADA did not appear to have a clinically signi fi cant impact on PK, safety or ef fi cacy (56, 59 – 62).”
InfluentialFrenking, J. H., Zhou, X., Rejeski, K., Wagner, V., Costello, P., Hielscher, T., Gatti, L., Kauer, J., Nadeem, O., Mai, E. K., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015732 · Cited by 17
“1,2 Safety and ef fi cacy of B-cell maturation antigen (BCMA) – targeted idecabtagene vicleucel (ide-cel) and cil-tacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma (RRMM) have been demonstrated in clinical trials 3,4 and real-world studies.”
Self-citationAzcona, M. S. R., Monaco, G., Whitehead, M., Kaufmann, M. M., Alzubi, J., Cathomen, T., & Mussolino, C. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102618 · Cited by 18
“37,38 Nevertheless, a lack of favorable response to the CAR T cell therapy has been observed due to a variety of mechanisms including antigen escape, tumor microenvironment immunosuppression, limited CAR T cell persistence, and the appearance of exhaustion.”
Steinhardt, M., Schaefers, C., Leypoldt, L., Blau, I., Harzer, M., Zhou, X., Riedhammer, C., Kamili, A., Kosch, R., Topp, L. S., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01330-9 · Cited by 17
Self-citationCo‐Delivery of Multiple RNAs via Lipid Nanoparticles Enables Precise Gene Editing of CAR‐T Cells
Wang, M., Liao, Q., Bai, S., Liu, X., Peng, Y., Liu, P., Lu, H., Zhu, J., & Zeng, C. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501475 · Cited by 17
Bernard, G., & Evgin, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664403 · Cited by 14
“…of hematological cancers, and there are seven Food and Drug Administration (FDA) approved therapies for relapsed/refractory acute lymphoblastic leukemia (ALL) (1 – 3), aggressive B cell lymphoma (4 – 6), mantle cell lymphoma (7), indolent B cell lymphoma (8, 9), and multiple myeloma (10 – 12).”
Clinical experience of CAR T cells for multiple myeloma
Simmons, G. L., Satta, T., & Puglianini, O. A. C. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101306 · Cited by 16
Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia
Heyman, B. M., Tzachanis, D., & Kipps, T. J. (2022) · Cancers · doi:10.3390/cancers14071715 · Cited by 17
“MRD—negative status was achieved in 26% of all patients who were treated and 79% who had a complete response or better [64].”
BackgroundArtificial intelligence and chimeric antigen receptor T-cell therapy
Gil, L., & Grajek, M. (2022) · Acta Haematologica Polonica · doi:10.5603/ahp.a2022.0019 · Cited by 16
Moving Toward a Cure for Myeloma
Mateos, M., Nooka, A. K., & Larson, S. M. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349603 · Cited by 20
Sellin, M., Berg, S. A., Hagen, P. A., & Zhang, J. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101448 · Cited by 17
Dalal, P., Patel, N. P., Feinstein, M. J., & Akhter, N. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221132927 · Cited by 17
“Idecabtagene vicleucel is approved for relapsed/ refractory multiple myeloma.(19,20) Its phase 2 study showed an overall response rate of 73%, a complete response rate of 33%, and an overall survival rate of 78% at 12 months.”
BackgroundSaldarriaga, M. M., Darwiche, W., Jayabalan, D. S., Monge, J., Rosenbaum, C. A., Pearse, R. N., Niesvizky, R., & Bustoros, M. W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1020011 · Cited by 16
“This study showed that 76% of patients achieved CR and 29% MRD-negative status maintained for up to 12 months (in 60% of MRD-negative patients) (106).”
Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
Yang, Z., & Wang, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002549 · Cited by 18
Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article
Hussain, M., Yellapragada, S. V., & Hadidi, S. A. (2023) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s272703 · Cited by 18
Giudice, M. L. D., Galimberti, S., & Buda, G. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03559-4 · Cited by 16
“Neither KArMMA1 nor CARTITUDE-1 enrolled this category of patients [45, 46], and this is why data focusing on this subject are of great interest [47–50].”
BackgroundAllogeneic CAR T Cell Therapy for Cancer
Sasu, B. J., Lauron, E. J., Schulz, T. F., Cheng, H., & Sommer, C. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062822-023316 · Cited by 16
Mikkilineni, L., Natrakul, D. A., Lam, N., Manasanch, E. E., Mann, J., Weissler, K. A., Wong, N., Brudno, J. N., Goff, S. L., Yang, J. C., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2023.12.018 · Cited by 16
Losurdo, A., Muzio, A. D., Cianciotti, B. C., Dipasquale, A., Persico, P., Barigazzi, C., Bono, B., Feno, S., Pessina, F., Santoro, A., et al. (2024) · Cancers · doi:10.3390/cancers16030603 · Cited by 16
“…approaches in hematological malignancies and the approval for clinical use in several countries of CAR-T therapy for the treatment of relapsed or refractory lymphomas, leukemia, or multiple myeloma [107–110], this specific ACT application has been under investigation in many different solid tumors.”
BackgroundManaging Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy
Ahmed, N., Oluwole, O. O., Mahmoudjafari, Z., Suleman, N., & McGuirk, J. P. (2024) · Clinical Hematology International · doi:10.46989/001c.115932 · Cited by 17
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma
Tacchetti, P., Talarico, M., Barbato, S., Pantani, L., Mancuso, K., Rizzello, I., Zamagni, E., & Cavo, M. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2344647 · Cited by 16
“Approval derives from the results of the phase 2 KarMMa trial (NCT03361748) [69], that enrolled RRMM patients who had received at least 3 previous regimens and who were TCE.”
BackgroundResultInfluentialSelf-citationImmunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells
Maldini, C. R., Messana, A., Bendet, P. B., Camblin, A. J., Musenge, F. M., White, M. L., Rocha, J. J., Coholan, L. J., Karaca, C., Li, F., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.06.022 · Cited by 18
“37,57,58 These fi ndings imply that transient immunosuppressant treatment, possibly 3 – 4 weeks, around the time of immune reconstitution would be critical to inhibit allorejec-tion, thereby permitting unhindered expansion of allogeneic CAR-T cells to drive deep initial responses.”
A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
Atrash, S., & Moyo, T. K. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s242018 · Cited by 16
Future Directions in Maintenance Therapy in Multiple Myeloma
Holstein, S. A., Suman, V. J., Hillengass, J., & McCarthy, P. L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112261 · Cited by 17
“However as induction regimens continue to evolve (e.g., quadruplet combinations such as Dara-RVD [29] or Dara-KRd [54]), as well as the advent of new cellular therapies (such as CAR T-cells [55]) and bispecific agents [56,57], the question remains whether routine use of upfront ASCT will diminish over time.”
BackgroundHarnessing the Immune System to Fight Multiple Myeloma
Krejcik, J., Barnkob, M. B., Nyvold, C. G., Larsen, T. S., Barington, T., & Abildgaard, N. (2021) · Cancers · doi:10.3390/cancers13184546 · Cited by 16
“So far, only one of them, idecabtagene vicleucel, has received FDA approval based on recently published results from a phase 2 study (NCT03361748) [97,98], and ciltacabtagene autoleucel has earned FDA priority review [99], both for the indication of relapsed/refractory MM.”
BackgroundMaakaron, J. E., Hu, M., & Jurdi, N. E. (2022) · BMJ · doi:10.1136/bmj-2021-068956 · Cited by 19
Wang, J., Gu, T., Hu, Y., & Huang, H. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00316-8 · Cited by 16
“NA not applicable Clinical trials (reference) MCARH109 [68] Ide‐Cel (KarMMA) [67] Cilta‐Cel (CARTITUDE‐1) [69, 112] Cilta‐Cel (CARTITUDE‐2) [73] CT053 (Lummicar and CG study) [70] CT103A [76, 77] bb21217 (CRB‐402) [75]”
BackgroundGerber, W. K., Xie, Y., & Patel, S. A. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00753 · Cited by 17
Saha, S., Rehman, L., Rehman, A., Darbaniyan, F., Weber, D. M., Becnel, M., Gaballa, M., Thomas, S. K., Lee, H. C., Chang, C., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014476 · Cited by 15
Fang, W. J., Lu, Z., Ge, J., Zhang, S., Zheng, R., Yin, W., Hao, R., Sun, M., & Luo, T. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.014 · Cited by 15
On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models
Birocchi, F., Almazan, A. J., Parker, A., Bouffard, A. A., Goncalves, S., Kelly, C., Frank, J. A., Leick, M. B., Haradhvala, N. J., Kagawa, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61858-z · Cited by 18
“CAR-T cell counts in the peripheral blood were measured by fl ow cytometry at days 7, 14, and 21 post-injection.”
Current state of CAR-T cell therapies for solid tumors
Rosa, R. C. A., Liu, J., Lu, C., Abou‐El‐Enein, M., Murad, J. P., & Priceman, S. J. (2026) · Med · doi:10.1016/j.medj.2026.101028 · Cited by 21
Sun, Z., & Liu, M. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.03.009 · Cited by 16
Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy
Gill, J. (2022) · Current Cardiology Reviews · doi:10.2174/1573403x18666220623152350 · Cited by 16
“Data from the landmark clinical trials, which led to the United States Food and Drug Administration (FDA) approval of the current CAR T-cell therapies, are presented in Table 2 [23, 24, 59-62].”
MethodEpigenetic engineering for optimal chimeric antigen receptor T cell therapy
Ito, Y., & Kagoya, Y. (2022) · Cancer Science · doi:10.1111/cas.15541 · Cited by 14
Ayers, D., Cope, S. F., Towle, K. M., et al. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01745-z · Cited by 15
“Ide-cel demonstrated frequent, deep, and durable responses in TCE patients with RRMM based on the pivotal, phase 2, single-arm KarMMa trial (NCT03361748) [22].”
BackgroundStaupe, R. P., Lodge, K. E., Thambi, N., Toole, D., Tamburino, A. M., Chang, D., Howell, B. J., Hazuda, D. J., Vora, K. A., & Sullivan, N. (2022) · Communications Biology · doi:10.1038/s42003-022-04216-9 · Cited by 14
“Expression of BCMA , CXCR4 , the two subunits of VLA-4 ( ITGA4 and ITGB1 ), and SDC1 which encodes for CD138 were observed at the RNA level within the LLPC cluster (Fig.”
Highlights into historical and current immune interventions for cancer
Cole, K., Al-Kadhimi, Z. S., & Talmadge, J. E. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109882 · Cited by 15
Hua, G., Scanlan, R., Straining, R., et al. (2023) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2023.14.2.7 · Cited by 15
“Most notably, the grade ≥ 3 CRS rates have appeared more frequency in clinical trials involving anti-BCMA CAR T-cell therapies (Berdeja et al., 2021; Munshi et al., 2021).”
BackgroundConsiderations and Approaches for Cancer Immunotherapy in the Aging Host
Ontiveros, C. O., Murray, C. E., Crossland, G. E., & Curiel, T. J. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0121 · Cited by 16
Branella, G. M., Lee, J. Y., Okáľová, J., Parwani, K. K., Alexander, J. S., Arthuzo, R. F., Fedanov, A., Yu, B., McCarty, D., Brown, H. C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294555 · Cited by 15
Qian, H., Yang, X., Zhang, T.-T., Zou, P., Zhang, Y., Tian, W., Mao, Z., & Wei, J. (2024) · American Journal of Hematology · doi:10.1002/ajh.27198 · Cited by 15
Thirumalaisamy, R., Vasuki, S., Sindhu, S., Mothilal, T. M., Srimathi, V., Poornima, B., Bhuvaneswari, M., & Hariharan, M. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01090-0 · Cited by 17
“It is a genetically modified CAR-T Cell therapy which is directed by B-Cell maturation antigen (BCMA) based on the risk evaluation and mitigation strategies (CARVYKTI) is approved [13].”
Martino, E. A., Vigna, E., Bruzzese, A., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., Zimbo, A. M., Torricelli, F., Neri, A., et al. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2333376 · Cited by 17
“While selinexor has demonstrated significant progress in MM treatment, it is essential to contextualize selinexor efficacy concerning other advanced therapies such as CAR-T therapy and ASCT [96,97].”
BackgroundPerl, M., Herfeld, K., Harrer, D. C., Höpting, M., Schweiger, M., Sterz, U., Knödler, L., Heimerl, S., Hansmann, L., Herr, W., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284564 · Cited by 20
“The adoptive transfer of chimeric antigen receptor (CAR)-modified T cells is a breakthrough for the treatment of relapsed/refractory lymphoma, 1,2 multiple myeloma, 3 and acute lymphoblastic leukemia, 4 and is a subject of research in different solid tumors.”
BackgroundRole of Immune Cells and Immunotherapy in Multiple Myeloma
Radhakrishnan, V., Golla, U., & Kudva, A. K. (2024) · Life · doi:10.3390/life14040461 · Cited by 18
Recent advances and progress in immunotherapy of solid cancers
Kumar, A., Emdad, L., Das, S. K., & Fisher, P. B. (2024) · Advances in cancer research · doi:10.1016/bs.acr.2024.05.004 · Cited by 15
Peng, X., Zhang, X., Zhao, M., Chang, D., Yang, L., Mei, H., & Zhang, R. (2024) · British Journal of Haematology · doi:10.1111/bjh.19583 · Cited by 15
“6,7,29,31 These occurrences often lead to life-threatening consequences.”
Coffey, D. G., Atilla, P. A., Atilla, E., Landgren, O., Cowan, A. J., Simon, S., Pont, M. J., Comstock, M., Hill, G. R., Riddell, S. R., et al. (2024) · Blood · doi:10.1182/blood.2024025231 · Cited by 17
Targeting cardiac fibrosis with Chimeric Antigen Receptor-Engineered Cells
Zhang, Q., Dai, J., Liu, T., Rao, W., Li, D., Gu, Z., Huang, L., Wang, J., & Hou, X. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05134-6 · Cited by 15
Self-citationCAR T-Cell Therapy: Updates in Nursing Management
Baer, B. (2021) · Clinical journal of oncology nursing · doi:10.1188/21.cjon.255-258 · Cited by 15
Costa, B. A., Mouhieddine, T. H., & Richter, J. R. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00897-8 · Cited by 17
“From the first description of MM in the literature as part of Samuel Solly’s case series in 1844 [7] to the landmark trial that confirmed the safety and efficacy of the chimeric antigen receptor (CAR) T-cell idecabtagene vicleucel (idecel) in 2021 [8], remarkable advances have been made in elucidating the clinicopatho…”
BackgroundLi, D., Que, Y., Ding, S., Hu, G., Wang, W., Mao, X., Wang, Y., Li, C., Huang, L., Zhou, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005403 · Cited by 14
Self-citationNK cell therapy in relapsed refractory multiple myeloma
Roshandel, E., Nazari, H. G., Mohammadian, M., Salimi, M., Abroun, S., Mirfakhraie, R., & Hajifathali, A. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109168 · Cited by 16
Fitness and frailty in myeloma
Pawlyn, C., Khan, A., & Freeman, C. L. L. (2022) · Hematology · doi:10.1182/hematology.2022000346 · Cited by 16
T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma
Mailankody, S., & Landgren, O. (2022) · New England Journal of Medicine · doi:10.1056/nejme2209692 · Cited by 16
Russell, G. C., Hamzaoui, Y., Rho, D., Sutrave, G., Choi, J. S., Missan, D., Reckard, G. A., Gustafson, M. P., & Kim, G. B. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.03.484 · Cited by 15
Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study
Akhtar, O. S., Oloyede, T., Brazauskas, R., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014970 · Cited by 14
Self-citationIn vivo production of CAR T cell: Opportunities and challenges
Song, Z., Zhou, Y., Wang, B., Geng, Y., Tang, G., Wang, Y., & Yang, J. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101612 · Cited by 17
Clinical development of allogeneic chimeric antigen receptor αβ-T cells
Georgiadis, C., Preece, R., & Qasim, W. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.040 · Cited by 17
Daniele, P., Mamolo, C. M., Cappelleri, J. C., BELL, T. J., Neuhof, A., Tremblay, G., Musat, M. G., & Forsythe, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267979 · Cited by 13
“While treatment type was considered in the adjusted models, there was insufficient data with respect to chimeric antigen receptor T-cell (CAR T-cell) therapy to account for the possible disease-modifying effect of this potentially transformative treatment [34, 35].”
MethodFully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology
Lontos, K., Wang, Y., Colbert, M., Kumar, A., Joshi, S. K., Philbin, M., Wang, Y., Frisch, A. T., Lohmueller, J. J., Rivadeneira, D. B., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2131229 · Cited by 16
Shen, Y., Liu, J., Wang, B., Zhang, Y., Xu, Y., Wang, X., Jia, Y., Meng, X., Wang, X., Fan, X.-H., et al. (2023) · Current Research in Translational Medicine · doi:10.1016/j.retram.2023.103378 · Cited by 14
Krishnan, A. Y., Nooka, A. K., Chari, A., Garfall, A. L., Martin, T. G., Nair, S. C., Lin, X., Qi, K., Londhe, A., Pei, L., et al. (2023) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2022-0186 · Cited by 15
“Chimeric antigen receptor T-cell (CAR-T) therapies such as ciltacabtagene autoleucel and idecabtagene vicleucel have demonstrated substantial improvements in response rates (97.9 and 73%, respectively) and OS (OS not reached and 19.4 months, respectively) in this population [9 , 10] .”
BackgroundInfluentialHtut, M., Dhakal, B., Cohen, A., Martin, T., Berdeja, J., Usmani, S., Agha, M., Jackson, C., Madduri, D., Deraedt, W., et al. (2023) · Clinical Lymphoma, Myeloma & Leukemia · doi:10.1016/j.clml.2023.08.012 · Cited by 13
Self-citationKathari, Y. K., Ahmad, H., Kallen, M. E., Koka, R. M., Omili, D. O., Iraguha, T., Clement, J., Pham, L., Khalid, M., Fan, X., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283296 · Cited by 14
“Recently, the FDA approved idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for MM (2, 3), however, further research is needed to fully understand the long-term safety and efficacy of these treatments.”
BackgroundAnalysis of Updates in Multiple Myeloma Treatment and Management
Nieto, M. J., Hedjar, A., Locke, M., Caro, J., & Saif, M. W. (2023) · Journal of Clinical Haematology · doi:10.33696/haematology.4.055 · Cited by 14
“…as idecabtagene vicleucel), has shown good responses in patients with refractory/relapsed MM, many of whom were pretreated with numerous regimens prior; MRD-negative status was obtained in 26% of patients who were treated, with a median PFS of 8.8 months (95% confidence interval, 5.6 to 11.6) [26].”
BackgroundInfluentialAdoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
Vu, S. H., Pham, H. H., Pham, T. T. P., Le, T. T., Vo, M.-C., Jung, S., Lee, J., & Nguyen, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1275076 · Cited by 14
Noninvasive longitudinal PET/CT imaging of CAR T cells using PSMA reporter gene
Song, X., Zhang, Y., Lv, X., Xu, Z., Yu, L., Gai, Y., Jiang, D., Lei, P., & Lan, X. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06508-6 · Cited by 14
“Since 2017, several CAR T-cell therapies have been approved by the Food and Drug Administration (FDA), which are engaged in the treat-ment of hematological malignancies, including lymphomas, leukemia expressing CD19 [3–6], and multiple myeloma with B cell maturation antigen [7, 8].”
Bridging treatment prior to chimeric antigen receptor T‐cell therapy in multiple myeloma
Bal, S., & Costa, L. J. (2023) · British Journal of Haematology · doi:10.1111/bjh.19227 · Cited by 14
Wang, Q., Wei, R., Guo, S.-F., Min, C., Zhong, X., Huang, H., & Zhi, C. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00712-0 · Cited by 14
Emerging Biomarkers for Monitoring Chimeric Antigen Receptor T-Cell Therapy
Mamo, T., Dreyzin, A., Stroncek, D. F., & McKenna, D. H. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvad179 · Cited by 14
Shahzad, M., Khalid, M. F., Amin, M. K., Basharat, A., Ammad-Ud-Din, M., Park, R., Anwar, I., Faisal, M. S., & Jaglal, M. V. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.01.006 · Cited by 14
Soltantabar, P., Sharma, S., Wang, D., Lon, H., Czibere, A. G., Hickman, A., & Elmeliegy, M. A. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3223 · Cited by 19
Hadiloo, K., Taremi, S., Safa, S. H., Amidifar, S., & Esmaeilzadeh, A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107158 · Cited by 14
CAR-T Cell Therapy in Pancreatic and Biliary Tract Cancers: An Updated Review of Clinical Trials
Drougkas, K., Karampinos, K. I., Karavolias, I., Gomatou, G., Koumprentziotis, I., Ploumaki, I., Triantafyllou, E., & Kotteas, E. A. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01054-2 · Cited by 15
“Following this first FDA approval, five more CAR-T cell products have become available for various hematological malignancies [9–14].”
InfluentialOvercoming the challenges of primary resistance and relapse after CAR-T cell therapy
Dreyzin, A., Rankin, A. W., Luciani, K., Gavrilova, T., & Shah, N. N. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2349738 · Cited by 17
Self-citationMartín-Antonio, B., Blanco, B., González‐Murillo, Á., Hidalgo, L., Minguillón, J., & Pérez-Chacón, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1386856 · Cited by 14
Kfir-Erenfeld, S., Asherie, N., Lebel, E., Vainstein, V., Assayag, M., Sharon, T. D., Grisariu, S., Avni, B., Elias, S., Alexander-Shani, R., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012967 · Cited by 12
“4,7 The reduced HBI0101-related neurotox-icity reported herein will be the matter of a future investigation.”
Pak, W. L. W., Brumwell, N. A., Kabel, C. C., et al. (2024) · Kidney Medicine · doi:10.1016/j.xkme.2024.100856 · Cited by 14
Bar, N., Diels, J., Sanden, S. V., Mendes, J., Hernando, T., Burnett, H. F., Cost, P., Schecter, J. M., Lendvai, N. K., Patel, N., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2391112 · Cited by 14
Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers
AHMED, M. A., Krishna, R., Rayad, N., Albusaysi, S., Mitra, A., Shang, E. Y., Hon, Y. Y., Abuasal, B., Bakhaidar, R. B., Roman, Y. M., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3407 · Cited by 15
“65”
Kortleve, D., Hammerl, D., van Brakel, M., Wijers, R., Roelofs, D., Kroese, K., Timmermans, M. M., Liao, C., Huang, S., Trapman-Jansen, A., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0168 · Cited by 15
Guerrero-Murillo, M., Rill, A., Trincado, J. L., Bataller, Á., Ortiz‐Maldonado, V., Benítez‐Ribas, D., Español‐Rego, M., González‐Navarro, E. A., Martínez‐Cibrián, N., Marchese, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101803 · Cited by 14
Zhou, M., Huang, Z., Ma, Z., Chen, J., Lin, S., Yang, X., Gong, Q., Braunstein, Z., Wei, Y., Rao, X., et al. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.49 · Cited by 17
Sun, K.-H., Wong, Y.-T., Cheung, K. M., Yuen, C. M., Chan, Y.-T., Lai, W.-Y. (., Chao, C. (., Fan, W.-S., Chow, Y.-K., Law, M. F., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12020409 · Cited by 15
Emodin Ameliorates the Efficacy of Carfilzomib in Multiple Myeloma Cells via Apoptosis and Autophagy
Hsu, C., Yen, C., Wang, S., Liu, Y., Huang, C.-T., Wang, M., Chuang, B. T.-M., Ke, Y., Yeh, T., Gau, Y., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071638 · Cited by 14
Deng, J., Lin, Y., Zhao, D., Tong, C., Chang, A. H., Chen, W.-M., & Gao, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.901266 · Cited by 16
Self-citationGhanem, B., & Shi, L. (2022) · BioDrugs · doi:10.1007/s40259-022-00557-3 · Cited by 14
“The analysis method used in this study is based on the pivotal clinical trials of ciltacabtagene autoleucel (NCT03548207) and idecabtagene vicleucel (NCT03361748) [16, 17].”
BackgroundMethod
Metadata
- Authors
- Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H., Weisel, K., Rambaldi, A., Reece, D., Petrocca, F., Massaro, M., Connarn, J. N., Kaiser, S., Patel, P., Huang, L., Campbell, T. B., Hege, K., & San-Miguel, J.
- Affiliations
- Harvard University (US)
- Mayo Clinic (US)
- Hackensack University Medical Center (US)
- From the Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute (N.C.M.), the Veterans Affairs Boston Healthcare System, Harvard Medical School (N.C.M.), and Massachusetts General Hospital (N.R.), Boston, and bluebird bio, Cambridge (F.P., M.M.) — all in Massachusetts; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.); the University of California, San Francisco, San Francisco (N.S.); Icahn School of Medicine at Mount Sinai, New York ...
- ORCID
- Munshi, Nikhil C.
- Anderson, Larry D.
- Shah, Nina
- Madduri, Deepu
- Berdeja, Jesús
- Lonial, Sagar
- Raje, Noopur
- Lin, Yi
- Siegel, David
- Oriol, Albert
- Moreau, Philippe
- Yakoub-Agha, Ibrahim
- Delforge, Michel
- Einsele, Hermann
- Goldschmidt, Hartmut
- Weisel, Katja
- Rambaldi, Alessandro
- Reece, Donna
- Petrocca, Fabio
- Connarn, Jamie N.
- Kaiser, Shari
- Patel, Payal
- Huang, Liping
- Campbell, Timothy B.
- Hege, Kristen
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-25
- Volume
- 384
- Issue
- 8
- Pages
- 705-716
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3133229959
- Semantic Scholar
- fd96e2f87dff7d1153a17b78b56fbbab69cb714e
- Cited by
- 2,560
- References
- 17
- Citations by year
- 2026: 411 · 2025: 486 · 2024: 540 · 2023: 493 · 2022: 436 · 2021: 186
- FWCI
- 150.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- idecabtagene vicleucel, CAR T-cell therapy, relapsed/refractory multiple myeloma, BCMA, minimal residual disease, cytokine release syndrome, neurotoxicity, CAR T cell persistence, progression-free survival, complete response, neutropenia, anemia, thrombocytopenia, chimeric antigen receptor T cells
- MeSH terms
- Receptors, Chimeric Antigen, Progression-Free Survival, Cytokine Release Syndrome, Adult, Aged, Female, Hematologic Diseases, Humans, Male, Middle Aged, Multiple Myeloma, Recurrence, Biomarkers, Immunotherapy, Adoptive, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
